Some biomarkers associated with physical frailty and sarcopenia have been identified, such as gut bacteria and markers of inflammation [15], as well as C-reactive protein (CRP) [15,16], also a marker of muscle wasting in cancer cachexia [17], but longitudinal patient studies are yet to be undertaken to evaluate the potential of these biomarkers to predict onset, treatment response and the progression of such muscle wasting disease. The gene discussed is CRP; the disease is cancer.